- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma


Dr Ian Hudson to lead the MHRA

MHRA Annual Report Former paediatrician and pharmaceutical industry researcher Dr Ian Hudson has been appointed as Chief Executive of the Medicines and Healthcare Products Regulatory Agency (MHRA).

Currently the MHRA’s Licensing Director with chief responsibility for licensing of medicines in the UK, Dr Hudson will take over as Chief Executive in September.

The Agency’s current Chief Executive, Sir Kent Woods, is due to step down after ten years of leading the MHRA.

An executive agency of the Department of Health, the MHRA regulates medicines and medical devices to ensure their safety and efficacy. Unlike NICE, it does not recommend products on the basis of cost-effectiveness.

Dr Hudson is the UK delegate to the Committee on Human Medicinal Products (CHMP) at the European Medicines Agency.

Lord Howe, Health Minister, said: “The MHRA carries out vital work to protect the health and wellbeing of people by ensuring medicines and medical devices work and are acceptably safe.

“Dr Hudson is used to working to the highest possible standards and maintaining the very toughest scrutiny over a fast-moving industry, and I am confident he will find this role a deeply rewarding challenge.”

MHRA Chairman Sir Gordon Duff commented: “Dr Hudson has excellent, broad experience across all aspects of medicines regulation and is ideally placed to lead the MHRA, which is unique in bringing together medicines and medical devices regulation together with world-class research facilities and expertise.”

Dr Hudson practiced as a paediatrician for a number of years, then worked in the pharmaceutical industry in clinical R&D from 1989–2001 before joining the Medicines Control Agency, which later became the MHRA.

- Advertisement -


- Advertisement -



Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription